Navigation Links
NiKem Research receives certification for GLP Bioanalysis
Date:9/16/2009


Milan, September 16th 2009 / b3c newswire / - NiKem Research is pleased to announce that it has received, from the Italian Ministry of Health, GLP certification of its bioanalysis facilities to further extend its drug discovery service capabilities.

NiKem Research has provided for many years high quality cost-effective bioanalytical support both for its in vitro ADME(T) and in vivo PK servicesassociated to various drug discovery programs and as a standalone capability. We are now able to offer, as a new product, our bioanalysis as a GLP service to support our clients preclinical PK and toxicology studies. Our new capability allows us to analyse biological samples from all preclinical species, in particular we can:

* Provide GLP method development by HPLC or UPLC/MS/MS;
* Resolve clients analytical bottlenecks by providing GLP bioanalytical support for GLP samples sent by the client;
* Provide, in partnership with EU based companies, specialized in GLP animal dosing, a complete preclinical PK and Toxicokinetic GLP service with NiKem providing the GLP bioanalysis and project co-ordination.

Giuseppe Giardina, CEO & Managing Director of NiKem, said This new product is an important step in NiKems continuing expansion of its high quality, cost effective services to support progression of our clients drug discovery programmes.



About NiKem Research - www.nikemresearch.com
Based on decades of drug discovery experience, NiKem Research offers a full range of Drug Discovery services to the pharmaceutical industry. In addition to its medicinal chemistry expertise in hit validation and multiparametric lead optimization, NiKem Research offers synthetic chemistry and parallel synthesis capabilities and computational and analytical chemistry services. Furthermore, ADMET profiling, biochemical pharmacology screening and in vivo PK services can be provided either as an integrated Drug Discovery platform, or as individual service modules. NiKem Research usually operates as a fee-for-service partner although other business models can be used to ensure maximum value to our clients. All tangible and intangible assets generated during a collaboration are assigned to the client.



Contact
NiKem Research s.r.l.
Dr. Massimo Dondio
Director of Developability Sciences
Tel. +39 02 35694 7460,
Fax +39 02 35694 7606
massimo.dondio@nikemresearch.com
'/>"/>

b3c newswire

Related biology news :

1. Research shows skeleton to be endocrine organ
2. Newly created cancer stem cells could aid breast cancer research
3. Dominant cholesterol-metabolism ideas challenged by new research
4. Researchers identify proteins involved in new neurodegenerative syndrome
5. Texas researchers and educators head for Antarctica
6. MGH researchers describe new way to identify, evolve novel enzymes
7. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
8. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
9. U of MN researchers discover noninvasive diagnostic tool for brain diseases
10. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
11. Story ideas from the Journal of Lipid Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology: